GGHC
CCCC icon

Gilder Gagnon Howe & Co’s C4 Therapeutics CCCC Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,628
Closed -$646K – 255
2022
Q1 		$646K Buy
+26,628
New +$647K 0.01% 262
2021
Q4 		– Sell
-39,506
Closed -$1.76M – 398
2021
Q3 		$1.76M Buy
+39,506
New +$1.69M 0.01% 305

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Gilder Gagnon Howe & Co's CCCC Position: Q2 2022 in Review

Gilder Gagnon Howe & Co sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 26,628 shares — an estimated $646K sold.

Gilder Gagnon Howe & Co first reported a position in CCCC in Q3 2021 and held it in 2 quarters. The position peaked at $1.76M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Gilder Gagnon Howe & Co reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 26,628 C4 Therapeutics shares in Q2 2022, an estimated $646K.
  • Gilder Gagnon Howe & Co first reported a position in C4 Therapeutics in Q3 2021 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's C4 Therapeutics position peaked at $1.76M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2022, filed 15 Aug 2022.